GENOSS Coronary Stent Clinical Trial

Recruiting now · Not applicable

Conditions studied: Ischemic Heart Disease

In brief

This study aims to evaluate the efficacy and safety of abluminal biodegradable polymer ultrathin sirolimus-eluting stent (Genoss stent) as compared with a durable-polymer everolimus-eluting stent (Xience stent) in patients with coronary artery disease.

Key facts

Study ID

NCT05444452

Run by

Samsung Medical Center

People needed

850

Starts

2022-04-24

Expected to finish

2027-06-30

Last updated by the study team

2022-07-06

Who can join

Age: 19 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• ① Subject must be at least 19 years of age
• ② Subject who is able to understand risks, benefits and treatment alternatives and sign informed consent voluntarily.
• ③ Patients with stable coronary artery disease or acute coronary syndrome and at least one lesion with greater than 50% diameter stenosis suitable for stent implantation

You may not qualify if…

• Pregnant women ② Patients unable to provide consent, ③ Patients with known intolerance to aspirin, clopidogrel, ticagrelor, prasugrel, heparin or components of drug-eluting stents (sirolimus or everolimus)
• Patients who have non-cardiac co-morbid conditions with life expectancy <1 year or that may result in protocol non-compliance (per site investigator's medical judgment)

Where it is running

• Cardiac and Vascular Center; Samsung Medical Center — Seoul, South Korea (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.